Recent overviews on the drug delivery aspects and applications of brinzolamide for the management of glaucoma

Abstract

Brinzolamide (BRZ) is a highly selective carbonic anhydrase (CA) inhibitor which leads to decreases intraocular pressure (IOP) by slowing down the production of aqueous humour. It is indicated for the topical care of primary open-angle glaucoma (POAG) with ocular hypertension (OH), as 1% ocular suspension (Azopt) is applied twice or three times. A complex optic neuropathy known as POAG is characterized by the gradual loss of ganglion cells, including their axon. The main risk factor is elevated IOP, the only curable risk factor that can harm the optic head (ONH). To improve the absorption and bioavailability of BRZ in such eye-related complications, various drug delivery vehicles and nano-carriers such as Liposomes, In-situ Gelling systems, Nanofiber, TPGS-based nanoliposomes, Nanocapsules, Nanoemulsion, Niosomes and Nano lipid carrier are briefly suggested in the literature. Different strategies based on nano-carriers have shown to be successful for site-targeted delivery and demonstrate the basic structure with the altered pharmacodynamics property of BRZ. This review summarizes recent advancements in the management of glaucoma and the use of nano-carriers for molecular therapeutics of Glaucoma since it has distinct cellular targets, particularly the trabecular meshwork of the anterior portion of the eye.